Progress of anti-integrin drug risuteganib in the treatment of ocular fundus diseases
10.3760/cma.j.cn511434-20190821-00262
- VernacularTitle:抗整合素药物risuteganib治疗眼底疾病的研究现状与进展
- Author:
Yanan HU
1
;
Zhi ZHENG
Author Information
1. 上海交通大学附属第一人民医院眼科 上海市眼底病重点实验室 200080
- From:
Chinese Journal of Ocular Fundus Diseases
2020;36(10):813-816
- CountryChina
- Language:Chinese
-
Abstract:
Integrins is a family of multi-functional cell-adhesion molecules, heterodimeric receptors that connect extracellular matrix to actin cytoskeleton in the cell cortex, thus regulating various physiological and pathological processes. Risuteganib (Luminate ?) is a novel broad-spectrum integrin inhibitor. Based on multiple biological functions of anti-angiogenesis, vitreolysis, and neuroprotection, risuteganib is hopeful in treating several fundus diseases such as diabetic macular edema, vitreomacular traction, and non-exudative age-related macular degeneration. By far, risuteganib has successfully met the endpoints for three phase 2 studies and is preparing to enter the phase 3 of diabetic macular edema clinical trials. Overall the risuteganib is safe with no serious ocular or systemic adverse events. Given the unique mechanism of action and longer duration of efficacy, intravitreal injection of risuteganib has the potential to serve as a primary therapy, or adjunctive therapy to anti-VEGF agents.
